Insights

Spotlight: Featured on Self-Funded with Spencer Podcast

Brian Shonat, Goodroot’s area vice president of business development, recently joined Spencer Smith on the Self-Funded with Spencer podcast
Learn More

Levemir Discontinuation: What You Need to Know

Important update regarding a recent development about Novo Nordisk’s announcement to discontinue Levemir.
Learn More

Beyond Unit Cost: Evaluating Clinical Programs and Capabilities of PBMs

Here are three major factors brokers and employer groups should consider beyond unit cost when choosing a PBM.
Learn More

Medicaid AMP Cap Removal: Market Changes & Rx Strategies Amidst New Provisions

This article dives deep into these shifts and the subsequent reactions from industry stakeholders.
Learn More

AlignRx President & CEO Kevin Kobielski Recognized in 2023 BenefitsPRO Luminaries Awards

BenefitsPRO, the No.1 provider of news, analysis and trends for benefits professionals, has announced its 2023 Luminaries Awards recognizing excellence in the benefits industry.
Learn More

AlignRx Consulting Recognized on the 2023 Inc. 5000 List of Fastest Growing Companies

Inc. revealed today that AlignRx Consulting ranks No. 898 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America.
Learn More

The Cost Implications of New Weight Loss Treatments for Plan Sponsors

Obesity complications are a huge driver of healthcare costs. Could drugs in the latest generation of medications approved to promote weight loss be a
Learn More

Filter Insights:

Join our newsletter to stay up to date on market trends.

By subscribing you agree to with our Privacy Policy and provide consent to receive updates from our company.

Latest Clinical Insight

Why Your PBM May Be the Most Consequential Part of Your Health Plan

AlignRx is Now Navion